Daniel George, MD
CompanyROR
Daniel George, MD develops one asset. Mostly small molecule acting on AMPK signalling, Insulin/IGF-1 signalling and SLC5A2.
- Assets
- 1
- Furthest
- Not known
- Trials
- 6
- Signals
- 0
Pipeline
1Polypill containing an SGLT2 inhibitor, DPP-4 inhibitor, and biguanide for glycemic control.
Stage not knownSmall moleculeAMPK signallingInsulin/IGF-1 signalling
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms7
- Trials6
- Similar companies6
Updated 7 Oct 2026 · 11 sources